Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (407 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: dsm ivfailureunstablediagnosisexcluding
  Phrases that lowered it: individualsparticipantsparticipantopen labeldrug
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 14.7% (lowers risk) · Drug's FDA history
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 84.0% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Improved Strategies for Outpatient Opioid Detoxification NCT01377610 · started 2011 · scored riskier than 19% of active trials completed
• Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone NCT01882361 · started 2013 · scored riskier than 18% of active trials completed
• ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence NCT00678418 · started 2008 · scored riskier than 10% of active trials completed
• Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL NCT02696434 · started 2016 · scored riskier than 12% of active trials completed
• Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol NCT03113409 · started 2017 · scored riskier than 9% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.